NetraMark Holdings (TSE:AIAI) has released an update.
NetraMark Holdings has appointed Angelico Carta, co-founder of Worldwide Clinical Trials, as its Chief Strategy Officer to drive the company’s long-term strategy and growth. With over 35 years of experience in clinical development, Carta will leverage his vast expertise to enhance NetraMark’s AI-driven solutions in clinical trials and precision medicine. This strategic move aims to strengthen NetraMark’s leadership in the pharmaceutical industry and improve patient outcomes globally.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.